About this webinar:
Non-alcoholic steatohepatitis (NASH) is a highly prevalent disease, currently unmet therapeutically. NASH is characterized by fat accumulation in the liver leading to chronic fibrosis and inflammation, which can progress to cirrhosis and hepatocellular carcinoma.
Its progression is associated with fatty diets, dysregulation of metabolism and genetic predisposition. Several genes linked to NASH development are associated with lipid droplets, including HSD17B13 which encodes a metabolic enzyme in the lipid droplet membrane.
CN Bio’s liver-on-a-chip, cultured under a high fat stress, provides a human-relevant NASH model for characterizing drugs targeting metabolism. In this webinar, we highlight how the liver-on-a-chip system can be used to assess the impact of HSD17B13 inhibitors on fibrosis, human metabolism and lipid droplets.
Lead Scientist CRO Services
Chief Scientific Officer
Watch this webinar to find out how: